CYB5R4 Gene Methylation as a Potential Epigenetic Marker for Ovarian Cancer.

IF 1.9 4区医学 Q3 ONCOLOGY

Clinical Medicine Insights-Oncology Pub Date : 2025-06-20 eCollection Date: 2025-01-01 DOI:10.1177/11795549251340531

Aysegul Gonc, Ozge Sukruoglu Erdogan, Seda Kilic Erciyas, Betul Celik Demirbas, Ahmet Dinc, Ozge Pasin, Pınar Saip, Hulya Yazici, Seref Bugra Tuncer

{"title":"CYB5R4 Gene Methylation as a Potential Epigenetic Marker for Ovarian Cancer.","authors":"Aysegul Gonc, Ozge Sukruoglu Erdogan, Seda Kilic Erciyas, Betul Celik Demirbas, Ahmet Dinc, Ozge Pasin, Pınar Saip, Hulya Yazici, Seref Bugra Tuncer","doi":"10.1177/11795549251340531","DOIUrl":null,"url":null,"abstract":"Background: Ovarian cancer (OC) is a significant health problem often diagnosed at an advanced stage due to the lack of early symptoms and effective screening methods. This study aimed to explore the role of CYB5R4 gene methylation as a potential biomarker for ovarian cancer.Methods: DNA isolation was performed in the blood samples of 387 ovarian cancer patients, 50 individuals with benign ovarian diseases, and 100 healthy controls. The CYB5R4 gene methylation status was evaluated using the Methyl-Specific Restriction Enzymes (MSREs) technique and methylation levels were compared between the groups.Results: Ovarian cancer patients exhibited the highest mean methylation percentage (9.45%) and median (6.23%), followed by healthy controls with a mean of 9.14% and a median value of 4.47%. Statistical analysis showed significant differences in methylation levels (P = .041), suggesting that CYB5R4 methylation may be associated with ovarian cancer progression.Conclusion: The CYB5R4 gene methylation may serve as a potential biomarker for ovarian cancer, particularly in distinguishing between malignant and benign conditions. Further research is needed to validate these findings and explore the clinical utility of CYB5R4 methylation in ovarian cancer management.","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251340531"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181711/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11795549251340531","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Ovarian cancer (OC) is a significant health problem often diagnosed at an advanced stage due to the lack of early symptoms and effective screening methods. This study aimed to explore the role of CYB5R4 gene methylation as a potential biomarker for ovarian cancer.

Methods: DNA isolation was performed in the blood samples of 387 ovarian cancer patients, 50 individuals with benign ovarian diseases, and 100 healthy controls. The CYB5R4 gene methylation status was evaluated using the Methyl-Specific Restriction Enzymes (MSREs) technique and methylation levels were compared between the groups.

Results: Ovarian cancer patients exhibited the highest mean methylation percentage (9.45%) and median (6.23%), followed by healthy controls with a mean of 9.14% and a median value of 4.47%. Statistical analysis showed significant differences in methylation levels (P = .041), suggesting that CYB5R4 methylation may be associated with ovarian cancer progression.

Conclusion: The CYB5R4 gene methylation may serve as a potential biomarker for ovarian cancer, particularly in distinguishing between malignant and benign conditions. Further research is needed to validate these findings and explore the clinical utility of CYB5R4 methylation in ovarian cancer management.

Abstract Image

查看原文本刊更多论文

CYB5R4基因甲基化作为卵巢癌潜在的表观遗传标记。

背景：卵巢癌（OC）是一种重要的健康问题，由于缺乏早期症状和有效的筛查方法，往往在晚期诊断。本研究旨在探讨CYB5R4基因甲基化作为卵巢癌潜在生物标志物的作用。方法：对387例卵巢癌患者、50例卵巢良性疾病患者和100例健康对照进行DNA分离。采用甲基特异性限制性内切酶（MSREs）技术评估CYB5R4基因甲基化状态，并比较各组间甲基化水平。结果：卵巢癌患者的平均甲基化率最高（9.45%），中位数最高（6.23%），健康对照组的平均甲基化率为9.14%，中位数为4.47%。统计学分析显示甲基化水平存在显著差异（P = 0.041），提示CYB5R4甲基化可能与卵巢癌进展有关。结论：CYB5R4基因甲基化可能是卵巢癌的潜在生物标志物，特别是在区分恶性和良性疾病方面。需要进一步的研究来验证这些发现，并探索CYB5R4甲基化在卵巢癌治疗中的临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Medicine Insights-Oncology Medicine-Oncology

CiteScore

2.40

自引率

4.50%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.